# A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

> **NCT06532006** · PHASE3 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 550 (estimated)

## Conditions studied

- Gastroesophageal-junction Cancer
- Monoclonal Antibody
- Gastric Cancer
- HER2-positive Gastric Cancer

## Interventions

- **DRUG:** HLX22
- **DRUG:** Pembrolizumab
- **DRUG:** Trastuzumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06532006
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532006, "A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06532006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*